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1. The AA-induced aggregation measured by light transmission
aggregometry (LTA) is the most widely reported ex vivo
technique to assess aspirin effect in platelets (1–3). With
respect to our study potentially underestimating aspirin resis-
tance in patients with unstable coronary syndromes, it should
be noted that 23% (n  47) of our percutaneous coronary
intervention (PCI) patients were in that category. All of these
patients were sensitive to aspirin (4). To the best of our
knowledge, our prospective study is the largest reported in PCI
patients and is concordant with Schwartz et al (5), who
reported 1 of 190 patients resistant to aspirin using 1 mol/l
arachidonic acid (AA)-induced aggregation in platelet-rich
plasma. The latter investigators also reported that 9% of
patients exhibiting “resistance” were proven to be responders
after strict adherence to aspirin treatment. These data are
strikingly consistent with the results of our study (4).
2. Controversy remains regarding dose-dependent effects of as-
pirin on ex vivo platelet function. The latter effects may be
COX-1 independent. We are currently conducting a double
crossover study in outpatients that addresses these important
issues.
3. With respect to the relation of ex vivo AA-induced aggrega-
tion to clinical outcomes, the single patient who was aspirin-
resistant in our study had suffered a stent thrombosis. We
agree that large-scale studies are necessary to firmly link ex vivo
platelet function measurements to the occurrence of adverse
ischemic events.
4. With respect to the assertion that the thrombelastograph
(TEG) assay has not undergone extensive evaluation, it should
be noted that the TEG platelet mapping assay has been cleared
by the Food and Drug Administration as an automated platelet
aggregation system. As reported in our study, a statistically
significant correlation existed between measurements by LTA
and TEG (r 0.85; p 0.001). We are currently studying the
relation of TEG measurements to the occurrence of recurrent
ischemic events (6). The TEG has been used for many years to
guide therapy in patients with postsurgical bleeding.
5. We referred to a previous study of the VerifyNow assay
using propyl gallate (PG) as the agonist (7). There are no
published data correlating PG as an agonist to AA in the
measurement of aspirin resistance. At the time we submit-
ted our findings to JACC, PG was the only reported agonist
used in the VerifyNow assay to assess platelet responsive-
ness to aspirin. Moreover, no major studies describing the
new AA cartridge in the VerifyNow assay had occurred
prior to, and none have occurred since, our submission to
JACC.
6. The relation of aspirin dose to bleeding remains controversial.
We believe that this subject would be best addressed by
prospective studies and not by meta-analyses.
7. We agree that there is much confusion regarding aspirin
“resistance,” and this was indeed the stimulus to conduct our
investigation. Stimulation by multiple pathways will affect
measurements of ex vivo platelet function and the interpreta-
tion of drug “resistance.” A technique that isolates the specific
pathway targeted by the drug should be used to assess drug
response. Therefore, we believe that failure to inhibit the
primary target of aspirin (i.e., COX-1) should be the criterion
for aspirin resistance. The primary message of our study was
that the prevalence of aspirin resistance using this definition is
rare after treatment with a 325-mg daily dose.
Finally, we emphasize that aspirin resistance may be an impor-
tant phenomenon related to the occurrence of adverse clinical
events. A standardized definition that will employ validated
point-of-care methods to facilitate investigations in large-scale
clinical trials is needed. A critical assessment of pathways affected
by aspirin will also determine whether clinical events are only
related to incomplete platelet COX-1 inhibition or to other
anti-inflammatory or antioxidant properties of aspirin that may be
dose-dependent.
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Bifurcation Coronary
Lesions and the “Crush” Technique
We read with interest the study by Costa et al. (1) clarifying a
number of important aspects of the treatment of bifurcation lesions
by the crush technique. The investigators reported that “the
majority of SB (side branch) lesions showed stent underexpansion
with the smallest MSA (mean sent area) found at the SB ostium,”
and that this underexpansion was not reliably detected by angi-
ography. Given the potential implications of these findings on the
development of both stent thrombosis and restenosis at the ostium
of the SB, it would be interesting to know additional details on
how the crush technique was performed in this study. Bench-
testing has demonstrated procedural issues that maximize the
likelihood of adequate dilation of the SB ostium, including
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ensuring that the SB postdilation balloon is the same diameter or
larger than the deploying balloon (2).
In addition, Colombo (3) has described the importance of
performing “before kissing, a high-pressure balloon inflation in the
side-branch so as to be sure to expand the stent fully at the ostium.”
Costa et al. (1) also found that “incomplete stent apposition in the
crush area was common.” Some operators deliberately undersize
the main vessel (MV) balloon during kissing inflation to avoid
“oversizing” by the double balloons at the proximal end of the MV
stent. We have previously shown that this leads to MV stent
distortion (2,4) and incomplete crushing (2) and that these
outcomes can be prevented or repaired by kissing with appropri-
ately sized balloons in the MV and SB.
Finally, it is not clear whether Costa et al. (1): 1) performed a
separate high-pressure inflation in the SB before kissing; 2)
whether the MV and SB balloons were smaller, the same size, or
larger than the deploying balloons (the reported stent and final
balloon diameters are a mean of the study population); and 3) what
pressures were achieved in the SB and MV balloons during kissing
inflations. This information is particularly pertinent for those cases in
which the MSA of the SB ostium was 4 mm2 and when
incomplete crushing was observed.
*Duncan C. McNab, MB, BS, MPhil
John Ormiston, MB, ChB
Mark W. I. Webster, MB, ChB
*Auckland City Hospital
Cardiology
Park Road
Grafton
Auckland, 1005
New Zealand
E-mail: duncanmcn@adhb.govt.nz
doi:10.1016/j.jacc.2006.03.028
REFERENCES
1. Costa RA, Mintz GS, Carlier SG, et al. Bifurcation coronary lesions
treated with the “crush” technique—an intravascular ultrasound analy-
sis. J Am Coll Cardiol 2005;46:599–605.
2. Ormiston JA, Currie E, Webster MW, et al. Drug-eluting stents for
coronary bifurcations: insights into the crush technique. Catheter
Cardiovasc Interv 2004;63:332–6.
3. Colombo A. Bifurcational lesions and the “crush” technique: under-
standing why it works and why it doesn’t—a kiss is not just a kiss.
Catheter Cardiovasc Interv 2004;63:337–8.
4. Ormiston JA, Webster MWI, Ruygrok PN, et al. Stent deformation
following simulated side branch dilation: a comparison of five stent
designs. Catheter Cardiovasc Interv 1999;47:504–8.
REPLY
The investigators of the referenced study (1) thank McNab and
colleagues for their comments. Regarding questions about the
procedural “steps” and final kissing balloon (KB) inflation among
non-left main lesions (n  20) treated with sirolimus-eluting stent
(SES) crush stenting and final intravascular ultrasound (IVUS) in
both branches, the responses are as follows:
1. Only 40% (8 of 20 patients) had a separate high-pressure
inflation (12 atm) in the side branch (SB) before KB;
2. final KB inflation (90%) was performed in the main vessel
(MV) with a balloon of the same size as the “deployment”
balloon in 89% (16 of 18 patients), with a smaller balloon in
5.6% (1 of 18 patients), and with a larger balloon in 5.6% (1 of
18 patients);
3. final KB inflation was performed in the SB using a same-size
balloon (same as “deployment” balloon) in all but one case,
94.4% (17 of 18 patients); in one case a smaller balloon was
used;
4. the pressure of the KB inflation was 10.4 4.1 atm in the MV
and 14.3  3.8 atm in the SB.
When we consider these analyses in lesions with minimum stent
area (MSA) at the SB ostium 4 mm2 versus MSA 4 mm2, we
found:
1. similar rates of high-pressure balloon inflation in the SB prior
to KB (42% vs. 38%, p  0.8);
2. balloon pressure at the SB during KB was 14.6  3.8 atm (4
mm2) versus 15.6  2.8 atm (4 mm2), p  0.6.
In addition, a comparison of lesions with incomplete crush (IC)
versus “complete” crush (CC) showed that:
1. 33% of lesions with IC had SB high-pressure inflation before
KB versus 25% of lesions with CC, p  0.6;
2. IC had lower balloon pressure during KB in the SB (12.3 
3.7 atm for IC vs. 17  3.8 atm for CC; p  0.04).
Finally, we could not demonstrate any impact of high-pressure
balloon inflation in the SB before KB on final luminal dimensions
in the SB and on the incidence of IC; this may be due to the small
sample size. However, these results showed that higher balloon
pressures in the SB during KB inflation are associated with
complete “crush” stent apposition, indicating that IC is associated
with SB stent underexpansion (1).
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Secondary Stroke
Prevention and Antiplatelet Therapy
A truth that’s told with bad intent beats all the lies you can invent
—William Blake (1757–1827, Auguries of Innocence)
I was very disappointed to see JACC publish an opinion piece by
Dr. Gebel that is basically a cleverly disguised advertisement for
Aggrenox (1). Extended-release dipyridamole (ER-DP) and aspi-
rin is sold as Aggrenox, which is made by Boehringer Ingelheim,
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